Targeting the Fas/FasL signaling pathway in cancer therapy
- 12 January 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Emerging Therapeutic Targets
- Vol. 16 (1), 85-101
- https://doi.org/10.1517/14728222.2011.628937
Abstract
Introduction: The Fas/FasL system plays a significant role in tumorigenesis. Research has shown that its impairment in cancer cells may lead to apoptosis resistance and contribute to tumor progress...This publication has 142 references indexed in Scilit:
- Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptorLaboratory Investigation, 2011
- Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL)Archives of Biochemistry and Biophysics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Effect of the histone deacetylase inhibitor SNDX‐275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastasesCancer, 2011
- mir-200c Regulates Induction of Apoptosis through CD95 by Targeting FAP-1Molecular Cell, 2010
- Protective effects of HFE7A, mouse anti-human/mouse Fas monoclonal antibody against acute and lethal hepatic injury induced by Jo2Cytotechnology, 2009
- Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulationCell Death & Differentiation, 2009
- Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cellsCancer Gene Therapy, 2008
- microRNAs and death receptorsCytokine & Growth Factor Reviews, 2008
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993